We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) ended the recent trading session at $67.74, demonstrating a -6.98% change from the preceding day's closing price. This change lagged the S&P 500's 0.01% gain on the day. At the same time, the Dow added 0.51%, and the tech-heavy Nasdaq lost 0.28%.
Shares of the company have appreciated by 38.07% over the course of the past month, outperforming the Medical sector's gain of 4.67%, and the S&P 500's gain of 4.83%.
Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. The company is forecasted to report an EPS of -$1.32, showcasing a 30.69% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $7.71 million, indicating a 1185.5% increase compared to the same quarter of the previous year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$6.59 per share and a revenue of $33.41 million, representing changes of -51.84% and -10.47%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for CRISPR Therapeutics AG. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.48% lower. Right now, CRISPR Therapeutics AG possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 74, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
CRISPR Therapeutics AG (CRSP - Free Report) ended the recent trading session at $67.74, demonstrating a -6.98% change from the preceding day's closing price. This change lagged the S&P 500's 0.01% gain on the day. At the same time, the Dow added 0.51%, and the tech-heavy Nasdaq lost 0.28%.
Shares of the company have appreciated by 38.07% over the course of the past month, outperforming the Medical sector's gain of 4.67%, and the S&P 500's gain of 4.83%.
Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. The company is forecasted to report an EPS of -$1.32, showcasing a 30.69% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $7.71 million, indicating a 1185.5% increase compared to the same quarter of the previous year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$6.59 per share and a revenue of $33.41 million, representing changes of -51.84% and -10.47%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for CRISPR Therapeutics AG. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.48% lower. Right now, CRISPR Therapeutics AG possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 74, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.